At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,003 enrolled
Drug / intervention
silver salts coated endotracheal tube +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-center Clinical Trial of the Bard Silver-coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)
In Brief
A Phase 3 clinical trial evaluating silver salts coated endotracheal tube and uncoated endotracheal tube for Respiratory Failure. Completed, enrolled 2,003 participants across 5 sites.
Detailed Summary
The purpose of this study is to determine if the use of a silver-coated endotracheal tube (ETT) can reduce the incidence and/or delay the time of onset of VAP when compared to a non silver-coated ETT in patients who have been mechanically ventilated for \>= 24 hours.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Failure
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2002
First PostedSep 2005
Primary CompletionMar 2006
TodayJul 2026
First PostedSep 8, 2005
Enrollment StartNov 1, 2002
Primary CompletionMar 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.8 years ago
Interventions
silver salts coated endotracheal tubedevice
intubation with silver coated tube
uncoated endotracheal tubedevice
intubation